Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Imatinib, a Bcr-Abl tyrosine kinase inhibitor, initiated targeted therapy for chronic myelogenous leukemia (CML).
• Resistance mechanisms, both Bcr-Abl-dependent and independent, emerged against imatinib therapy.
• The development of second- and third-generation inhibitors was necessitated by imatinib resistance.

Purpose of the Study:

• To review the development of Bcr-Abl inhibitors for CML treatment.
• To elucidate the mechanisms of resistance and the design of subsequent inhibitors.
• To highlight the broader implications of Bcr-Abl inhibitor research for other kinase-targeted therapies.

Main Methods:

• Analysis of crystallographic data and structure-activity relationships.
• Review of clinical data for imatinib and subsequent Bcr-Abl inhibitors.
• Examination of preclinical data for emerging Bcr-Abl inhibitors.

Main Results:

• Imatinib's specificity for Bcr-Abl protein was established.
• Newer inhibitors like dasatinib, nilotinib, bosutinib, and ponatinib were developed to overcome resistance.
• Ongoing research into novel inhibitors like bafetinib and GNF-2 shows promise.

Conclusions:

• Structural insights and structure-activity relationships were crucial for designing effective Bcr-Abl inhibitors.
• Bcr-Abl inhibitor development serves as a model for overcoming resistance in targeted cancer therapy.
• These findings have implications for developing inhibitors against other kinases for chemotherapeutic applications.